Eosinophilic gastroenteritis: Pathogenesis, diagnosis, and treatment
暂无分享,去创建一个
K. Guan | Ji Li | G. Ruan | Shuang Liu | Tian-ming Xu | Jing-Nan Li | Kaiwen Li
[1] P. Merkel,et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis , 2022, Annals of the Rheumatic Diseases.
[2] J. Murray,et al. Eosinophilic Gastroenteritis: Using Presenting Findings to Predict Disease Course , 2021, Clinical and translational gastroenterology.
[3] Toshio Watanabe,et al. Gastrointestinal IgG4 Deposition Is a New Histopathological Feature of Eosinophilic Gastroenteritis , 2021, Digestive Diseases and Sciences.
[4] Emran El-Alali,et al. Successful use of montelukast in eosinophilic gastroenteritis: a case report and a literature review , 2021, BMC Gastroenterology.
[5] M. Buras,et al. Diagnosis of Pediatric Non-Esophageal Eosinophilic Gastrointestinal Disorders by Eosinophil Peroxidase Immunohistochemistry. , 2021, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.
[6] E. Dellon,et al. Peripheral eosinophilia and hypoalbuminemia are associated with a higher biopsy diagnostic yield for eosinophilic gastroenteritis. , 2021, Clinics and research in hepatology and gastroenterology.
[7] E. Israel,et al. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. , 2021, The New England journal of medicine.
[8] A. Verma,et al. Tacrolimus (FK506) treatment protects allergen‐, IL‐5‐ and IL‐13‐induced mucosal eosinophilia , 2021, Immunology.
[9] L. Gehman,et al. Diagnostic Delay in Patients with Eosinophilic Gastritis and/or Duodenitis: A Population-Based Study. , 2021, The journal of allergy and clinical immunology. In practice.
[10] Toshio Watanabe,et al. Endoscopic findings of gastric lesions in patients with eosinophilic gastrointestinal disorders , 2020, Endoscopy International Open.
[11] J. Murray,et al. Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis. , 2020, The New England journal of medicine.
[12] E. Dellon,et al. Mast Cell and Eosinophil Counts in Gastric and Duodenal Biopsies From Patients With and Without Eosinophilic Gastroenteritis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[13] A. Patereli,et al. Distribution of eosinophils in the gastrointestinal tract of children with no organic disease , 2020, Annals of gastroenterology.
[14] A. de Silvestri,et al. Epidemiology of non-esophageal eosinophilic gastrointestinal diseases in symptomatic patients: a systematic review and meta-analysis. , 2020, The journal of allergy and clinical immunology. In practice.
[15] T. Casale,et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma , 2020, Allergy.
[16] Michinobu Umakoshi,et al. Multiple ulcerations and perforation in the small intestine after steroid treatment in eosinophilic granulomatosis with polyangiitis: a case report and literature review. , 2019, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[17] C. Băicuș,et al. Eosinophilic pancreatitis versus pancreatitis associated with eosinophilic gastroenteritis – a systematic review regarding clinical features and diagnosis , 2019, Romanian journal of internal medicine = Revue roumaine de medecine interne.
[18] J. Krischer,et al. Association Between Endoscopic and Histologic Findings in a Multicenter Retrospective Cohort of Patients with Non-esophageal Eosinophilic Gastrointestinal Disorders , 2019, Digestive Diseases and Sciences.
[19] Garrett A. Osswald,et al. Molecular, Endoscopic, Histologic and Circulating Biomarker-Based Diagnosis of Eosinophilic Gastritis: Multi-Site Study. , 2019, The Journal of allergy and clinical immunology.
[20] G. Yancopoulos,et al. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. , 2019, Gastroenterology.
[21] C. Bebbington,et al. Siglec-8 antibody reduces eosinophil and mast cell infiltration in a transgenic mouse model of eosinophilic gastroenteritis. , 2019, JCI insight.
[22] M. Rezaei-Tavirani,et al. Evaluation of gene expression change in eosinophilic gastroenteritis , 2019, Gastroenterology and hepatology from bed to bench.
[23] Prashanth Rawla,et al. Eosinophilic gastroenteritis: diagnosis and clinical perspectives , 2019, Clinical and experimental gastroenterology.
[24] A. Straumann,et al. Eosinophilic Gastroenteritis: Clinical Manifestation, Natural Course, and Evaluation of Treatment with Corticosteroids and Vedolizumab , 2019, Digestive Diseases and Sciences.
[25] N. Gonsalves. Eosinophilic Gastrointestinal Disorders , 2019, Clinical Reviews in Allergy & Immunology.
[26] Yu Jin,et al. Abnormal thymic stromal lymphopoietin expression in the gastrointestinal mucosa of patients with eosinophilic gastroenteritis , 2019, Jornal de pediatria.
[27] G. Opiteck,et al. RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis. , 2019, Gastroenterology.
[28] Hiroki Sato,et al. Clinical and pathological profile of eosinophilic gastroenteritis , 2019, European journal of gastroenterology & hepatology.
[29] F. Bao,et al. The Anti-a4β7 Integrin Therapeutic Antibody for Inflammatory Bowel Disease, Vedolizumab, Ameliorates Eosinophilic Esophagitis: A Novel Clinical Observation , 2018, American Journal of Gastroenterology.
[30] G. Furuta,et al. Eosinophilic gastrointestinal diseases beyond eosinophilic esophagitis. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[31] F. Bao,et al. The Anti-α4β7 Integrin Therapeutic Antibody for Inflammatory Bowel Disease, Vedolizumab, Ameliorates Eosinophilic Esophagitis: a Novel Clinical Observation , 2018, The American Journal of Gastroenterology.
[32] M. Furue,et al. Mechanistic insights into topical tacrolimus for the treatment of atopic dermatitis , 2018, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[33] A. Peters,et al. Mepolizumab use: Post-approval academic practice experience. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[34] E. Dellon,et al. Vedolizumab Treatment May Reduce Steroid Burden and Improve Histology in Patients With Eosinophilic Gastroenteritis , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[35] C. Hui,et al. A Prospective Study on the Prevalence, Extent of Disease and Outcome of Eosinophilic Gastroenteritis in Patients Presenting with Lower Abdominal Symptoms , 2017, Gut and liver.
[36] A. Vanoli,et al. Association between defective spleen function and primary eosinophilic gastrointestinal disorders. , 2017, The journal of allergy and clinical immunology. In practice.
[37] G. Cooper,et al. Prevalence of Eosinophilic Gastroenteritis and Colitis in a Population‐Based Study, From 2012 to 2017 , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[38] E. Savarino,et al. Step‐up empiric elimination diet for pediatric and adult eosinophilic esophagitis: The 2‐4‐6 study , 2017, The Journal of allergy and clinical immunology.
[39] N. Ishimura,et al. Serum Biomarkers for the Diagnosis of Eosinophilic Esophagitis and Eosinophilic Gastroenteritis , 2017, Internal medicine.
[40] D. King,et al. Health‐Related Quality of Life and Costs Associated With Eosinophilic Esophagitis: A Systematic Review , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[41] J. Choung,et al. CCR3 Monoclonal Antibody Inhibits Eosinophilic Inflammation and Mucosal Injury in a Mouse Model of Eosinophilic Gastroenteritis , 2017, Allergy, asthma & immunology research.
[42] E. Dellon,et al. Food-specific IgG4 is associated with eosinophilic esophagitis. , 2016, The Journal of allergy and clinical immunology.
[43] K. Schenck,et al. Multiple Functions of the New Cytokine-Based Antimicrobial Peptide Thymic Stromal Lymphopoietin (TSLP) , 2016, Pharmaceuticals.
[44] Y. Ohya,et al. Sera of patients with infantile eosinophilic gastroenteritis showed a specific increase in both thymic stromal lymphopoietin and IL-33 levels. , 2016, The Journal of allergy and clinical immunology.
[45] K. Nadeau,et al. Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange , 2016, Nature Communications.
[46] Christopher F. Martin,et al. Prevalence of Eosinophilic Gastritis, Gastroenteritis, and Colitis: Estimates From a National Administrative Database , 2016, Journal of pediatric gastroenterology and nutrition.
[47] K. Lim,et al. Eosinophilic gastroenteritis: Clinical profiles and treatment outcomes, a retrospective study of 18 adult patients in a Singapore Tertiary Hospital. , 2015, The Medical journal of Malaysia.
[48] Reiji Kojima,et al. Racial differences in eosinophilic gastrointestinal disorders among Caucasian and Asian. , 2015, Allergology international : official journal of the Japanese Society of Allergology.
[49] R. Yu,et al. Eosinophilic gastroenteritis associated with eosinophilic cystitis: Computed tomography and magnetic resonance imaging findings. , 2015, World journal of gastroenterology.
[50] K. Nadeau,et al. Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. , 2015, The Journal of allergy and clinical immunology.
[51] J. Arm,et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects , 2014, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[52] F. Clayton,et al. Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE. , 2014, Gastroenterology.
[53] C. Lai,et al. Eosinophilic gastroenteritis with involvement of the urinary bladder , 2014, Pediatric Radiology.
[54] N. Ishimura,et al. Case-control study of association of eosinophilic gastrointestinal disorders with Helicobacter pylori infection in Japan , 2013, Journal of clinical biochemistry and nutrition.
[55] A. Straumann,et al. Anti‐eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis , 2013, Allergy.
[56] M. Vogel,et al. Accelerated Disassembly of IgE:Receptor Complexes by a Disruptive Macromolecular Inhibitor , 2012, Nature.
[57] James B. Young,et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. , 2012, The Journal of allergy and clinical immunology.
[58] P. Desreumaux,et al. Natural history of eosinophilic gastroenteritis. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[59] H. Ortega,et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. , 2011, Gastroenterology.
[60] B. Medoff,et al. 18F-FDG Uptake Rate Is a Biomarker of Eosinophilic Inflammation and Airway Response in Asthma , 2011, The Journal of Nuclear Medicine.
[61] D. Morgan,et al. Inverse association of esophageal eosinophilia with Helicobacter pylori based on analysis of a US pathology database. , 2011, Gastroenterology.
[62] Yuzhi Yin,et al. Effect of anti-IgE therapy on food allergen specific T cell responses in eosinophil associated gastrointestinal disorders , 2011, Clinical and molecular allergy : CMA.
[63] Samir S. Shah,et al. Variation in Prevalence, Diagnostic Criteria, and Initial Management Options for Eosinophilic Gastrointestinal Diseases in the United States , 2011, Journal of pediatric gastroenterology and nutrition.
[64] C. Prussin,et al. Eosinophilic gastrointestinal disease and peanut allergy are alternatively associated with IL-5+ and IL-5(-) T(H)2 responses. , 2009, The Journal of allergy and clinical immunology.
[65] C. Beglinger,et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial , 2009, Gut.
[66] G. Kearns,et al. Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: Effect on eosinophil density and activation in relation to pharmacokinetics , 2009, BMC gastroenterology.
[67] B. Ruebner,et al. Unusual presentations of eosinophilic gastroenteritis: case series and review of literature. , 2009, World journal of gastroenterology.
[68] K. Stone,et al. Immunomodulatory therapy of eosinophil‐associated gastrointestinal diseases , 2008, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[69] R. Weimann,et al. Corticosteroid-dependent eosinophilic oesophagitis: azathioprine and 6-mercaptopurine can induce and maintain long-term remission , 2007, European journal of gastroenterology & hepatology.
[70] Nayoung Kim,et al. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. , 2007, The Journal of allergy and clinical immunology.
[71] T. Sentongo,et al. Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[72] H. Simon,et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. , 2006, The Journal of allergy and clinical immunology.
[73] M. Rothenberg,et al. The α4bβ7‐integrin is dynamically expressed on murine eosinophils and involved in eosinophil trafficking to the intestine , 2006, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[74] J. Bousquet,et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. , 2005, The Journal of allergy and clinical immunology.
[75] S. Hogan,et al. Review article: the eosinophil as a therapeutic target in gastrointestinal disease , 2004, Alimentary pharmacology & therapeutics.
[76] B. Bochner,et al. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. , 2003, Blood.
[77] A. Zinsmeister,et al. Eosinophilic gastroenteritis: a clinicopathological study of patients with disease of the mucosa, muscle layer, and subserosal tissues. , 1990, Gut.
[78] M. Sleisenger,et al. EOSINOPHILIC GASTROENTERITIS , 1970, Medicine.
[79] L. Spencer,et al. Assessing Phenotypic Heterogeneity in Intestinal Tissue Eosinophils. , 2021, Methods in molecular biology.
[80] H. Sampson,et al. Adverse reactions to foods. , 2006, The Medical clinics of North America.